SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix announced that the Federal Circuit affirmed a district court…

CorMedix, Inc. · PRESS-RELEASE filed Jun 8, 2026 at 08:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 8, 2026 at 08:30 ET

CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity and infringement of its MINOCIN® patents against Nexus Pharmaceuticals, with a permanent injunction barring Nexus from marketing its generic minocycline product before patent expiration. This removes a key competitive threat to MINOCIN® revenue, protecting CorMedix's primary commercial asset. The ruling is a material positive for the company's intellectual property moat and near-term revenue outlook.

  • Federal Circuit affirmed district court judgment that MINOCIN® patents are valid and infringed by Nexus Pharmaceuticals.
  • Permanent injunction bars Nexus from marketing its generic minocycline product prior to patent expiration.
  • Patents-at-issue are FDA Orange Book listed, protecting MINOCIN® for Injection.
  • MINOCIN® is a tetracycline-derived antibiotic used in hospital and acute care settings for serious and drug-resistant infections.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access